This is in continuation to our letter dated 08th May, 2026, wherein we had informed regarding the audio link of the earnings call with analysts/investors for the quarter and financial year ....
INNOVACAP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Innova Captab reported FY '26 revenue of INR1,630 crores (31% YoY growth) with Q4 revenue at INR448 crores (42% YoY growth). CDMO business contributed INR1,133 crores (24% growth) while Branded Generics delivered INR497 crores (51% growth). EBITDA for the year stood at INR250.3 crores (15.4% margin) and PAT at INR140.9 crores (10% growth). The Jammu facility achieved INR300 crores full-year revenue and reached near EBITDA breakeven in Q4, with management confident of turning EBITDA positive in coming quarters. Sharon Bio contributed approximately INR240 crores with better margin profile. The company received UK-MHRA approval for its cephalosporin facility and PIC/S certification for Jammu blocks. Management guided for 20%+ revenue growth in FY '27 with EBITDA growth expected to outperform revenue growth as Jammu ramps up.
The company demonstrated strong operational performance with broad-based growth across both segments. Management's guidance of EBITDA outperformance versus revenue growth signals improving operating leverage as the Jammu facility scales up, which should benefit shareholders in FY '27.